Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

Research

Methicillin-Resistant Staphylococcus aureus, Samoa, 2007–2008

James Alesana-Slater, Stephen R. RitchieComments to Author , Helen Heffernan, Tracy Camp, Alice Richardson, Peter Herbison, and Pauline Norris
Author affiliations: Author affiliations: University of Otago, Dunedin, New Zealand (J. Alesana-Slater, P. Herbison, P. Norris); University of Auckland, Auckland, New Zealand (S.R. Ritchie); Institute of Environmental Science and Research Limited, Wellington, New Zealand (H. Heffernan, A. Richardson); Auckland City Hospital, Auckland (T. Camp)

Main Article

Table 1

Demographic characteristics of study participants and prevalence of MSSA and MRSA, Samoa, summer 2007–2008*

Characteristic Total study population No. (%, 95% CI)
S. aureus positive MSSA MRSA
No. participants
399
187 (47, 42–52)
153 (38, 34–43)
34 (9, 6–12)
Male sex
263
121 (46, 40–52)
95 (36, 31–42)
26 (10, 7–14)
Age, y†
<5 53 37 (70, 56–81)‡ 33 (62, 49–74) 4 (8, 3–18)
5–15 93 50 (54, 44–64) 44 (47, 38–57) 6 (7, 3–14)
16–59 195 79 (34–48) 60 (31, 25–38) 19 (10, 6–15)
>60
58
21 (36, 25–49)
16 (28, 18–40)
5 (9, 3–19)
Antimicrobial drug treatment in previous month 224 84 (38, 31–44)§ 67 (30, 24–36) 17 (8, 5–12)
Health care contact in previous 3 months 262 108 (41, 35–47) 85 (32, 27–38) 23 (9, 6–13)

*MSSA, methicillin-susceptible Staphylococcus aureus, MRSA, methicillin-resistant S. aureus; CI, confidence interval.
†Median age, y (range) of study participants: All, 32 (0–89); S. aureus positive, 24 (0–84); MSSA positive, 26 (0–84); MRSA positive, 36 (0–76).
‡p<0.001, S. aureus positive vs. study population >5 y of age.
§p<0.001, S. aureus positive vs. no antimicrobial drug treatment in the previous month.

Main Article

TOP